$SPRO
Spero Therapeutics, Inc.

2018 Q1 Form 10-K Financial Statement

#000156459018007402 Filed on April 02, 2018

View on sec.gov

Income Statement

Concept 2018 Q1 2017 2016 Q4
Revenue $1.153M $1.979M $335.0K
YoY Change 723.57% 490.75%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $3.040M $10.84M $2.220M
YoY Change 74.71% 50.14%
% of Gross Profit
Research & Development $8.925M $32.87M $6.930M
YoY Change 48.77% 24.82%
% of Gross Profit
Depreciation & Amortization $95.00K $363.0K $90.00K
YoY Change 9.2% 30.11%
% of Gross Profit
Operating Expenses $11.97M $43.71M $9.145M
YoY Change 54.66% 30.26%
Operating Profit -$10.82M -$41.73M
YoY Change 42.33% 25.61%
Interest Expense $172.0K $303.0K $620.0K
YoY Change -1663.64% -47.76%
% of Operating Profit
Other Income/Expense, Net $172.0K $1.844M $0.00
YoY Change -85.52% 217.93%
Pretax Income -$10.64M -$38.71M -$8.200M
YoY Change 65.99% 42.57%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$10.64M -$38.70M -$7.211M
YoY Change 81.14% 51.76%
Net Earnings / Revenue -923.16% -1955.53% -2152.54%
Basic Earnings Per Share
Diluted Earnings Per Share -$740.4K -$2.696M -$518.7K
COMMON SHARES
Basic Shares Outstanding 14.37M
Diluted Shares Outstanding

Balance Sheet

Concept 2018 Q1 2017 2016 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $75.40M $87.30M
YoY Change 747.57%
Cash & Equivalents $52.55M $87.30M $10.32M
Short-Term Investments $22.80M
Other Short-Term Assets $1.200M $1.800M
YoY Change 38.46%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $79.74M $92.10M $11.87M
YoY Change 673.95%
LONG-TERM ASSETS
Property, Plant & Equipment $1.070M $1.200M $1.500M
YoY Change -20.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $200.0K $300.0K
YoY Change 0.0%
Total Long-Term Assets $1.321M $1.400M $1.900M
YoY Change -26.32%
TOTAL ASSETS
Total Short-Term Assets $79.74M $92.10M $11.87M
Total Long-Term Assets $1.321M $1.400M $1.900M
Total Assets $81.06M $93.50M $13.77M
YoY Change 577.54%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $982.0K $3.500M $1.139M
YoY Change 218.18%
Accrued Expenses $4.500M $4.300M
YoY Change 48.28%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $5.834M $8.200M $6.918M
YoY Change 18.84%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $300.0K $400.0K
YoY Change -20.0%
Total Long-Term Liabilities $300.0K $400.0K
YoY Change -20.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $5.834M $8.200M $6.918M
Total Long-Term Liabilities $300.0K $400.0K
Total Liabilities $6.161M $8.900M $7.411M
YoY Change 147.22%
SHAREHOLDERS EQUITY
Retained Earnings -$107.5M -$45.44M
YoY Change
Common Stock $14.00K $0.00
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $74.54M $84.60M -$45.44M
YoY Change
Total Liabilities & Shareholders Equity $81.06M $93.50M $13.77M
YoY Change 577.54%

Cashflow Statement

Concept 2018 Q1 2017 2016 Q4
OPERATING ACTIVITIES
Net Income -$10.64M -$38.70M -$7.211M
YoY Change 81.14% 51.76%
Depreciation, Depletion And Amortization $95.00K $363.0K $90.00K
YoY Change 9.2% 30.11%
Cash From Operating Activities -$11.96M -$39.11M -$9.200M
YoY Change 71.36% 35.06%
INVESTING ACTIVITIES
Capital Expenditures $27.00K -$260.0K
YoY Change -96.75%
Acquisitions
YoY Change
Other Investing Activities -$22.83M
YoY Change
Cash From Investing Activities -$22.83M -$27.00K -$260.0K
YoY Change -96.75%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 116.1M 8.500M
YoY Change -100.0% 237.4%
NET CHANGE
Cash From Operating Activities -11.96M -39.11M -9.200M
Cash From Investing Activities -22.83M -27.00K -260.0K
Cash From Financing Activities 0.000 116.1M 8.500M
Net Change In Cash -34.79M 76.97M -960.0K
YoY Change -196.57% 1564.64%
FREE CASH FLOW
Cash From Operating Activities -$11.96M -$39.11M -$9.200M
Capital Expenditures $27.00K -$260.0K
Free Cash Flow -$39.14M -$8.940M
YoY Change 31.38%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2017 dei Amendment Flag
AmendmentFlag
false
CY2017 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2017 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2017 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2017 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2017Q2 dei Entity Public Float
EntityPublicFloat
0
CY2017 dei Trading Symbol
TradingSymbol
SPRO
CY2017 dei Entity Registrant Name
EntityRegistrantName
Spero Therapeutics, Inc.
CY2017 dei Entity Central Index Key
EntityCentralIndexKey
0001701108
CY2017 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2017 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2016Q4 us-gaap Other Receivables
OtherReceivables
304000
CY2017Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
87288000
CY2017 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2017
CY2017 dei Document Period End Date
DocumentPeriodEndDate
2017-12-31
CY2018Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
14369182
CY2017Q4 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
206000
CY2017 dei Document Type
DocumentType
10-K
CY2016Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
0
CY2016Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2017 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-17.82
CY2015 us-gaap Operating Income Loss
OperatingIncomeLoss
-13327000
CY2016 spro Fair Value Adjustment Of Derivative Liability
FairValueAdjustmentOfDerivativeLiability
-580000
CY2015 spro Fair Value Adjustment Of Derivative Liability
FairValueAdjustmentOfDerivativeLiability
-174000
CY2015 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2202000
CY2016 us-gaap Operating Expenses
OperatingExpenses
33556000
CY2016 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-7150000
CY2016 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7223000
CY2016 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
26333000
CY2015 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
11125000
CY2015 us-gaap Operating Expenses
OperatingExpenses
13327000
CY2016 us-gaap Operating Income Loss
OperatingIncomeLoss
-33221000
CY2017 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
303000
CY2017 us-gaap Net Income Loss
NetIncomeLoss
-38743000
CY2017 us-gaap Redeemable Preferred Stock Dividends
RedeemablePreferredStockDividends
6146000
CY2016 us-gaap Redeemable Preferred Stock Dividends
RedeemablePreferredStockDividends
3441000
CY2017 spro Accretion Of Redeemable Bridge Units And Redeemable Convertible Preferred Shares To Redemption Value
AccretionOfRedeemableBridgeUnitsAndRedeemableConvertiblePreferredSharesToRedemptionValue
1208000
CY2017 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-46097000
CY2017 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
2586865
CY2017Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2016Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1500000
CY2017Q4 us-gaap Common Stock Value
CommonStockValue
14000
CY2017Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
181428000
CY2016Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-45440000
CY2016Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
10315000
CY2017Q4 us-gaap Other Receivables
OtherReceivables
1011000
CY2017Q4 spro Tax Incentive Receivable Current
TaxIncentiveReceivableCurrent
1932000
CY2017Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1828000
CY2016Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1253000
CY2017Q4 us-gaap Assets Current
AssetsCurrent
92059000
CY2016Q4 us-gaap Assets Current
AssetsCurrent
11872000
CY2016Q4 spro Tax Incentive Receivable Noncurrent
TaxIncentiveReceivableNoncurrent
144000
CY2017Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
50000
CY2016Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
50000
CY2016Q4 us-gaap Assets
Assets
13772000
CY2016Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1139000
CY2016Q4 spro Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
2928000
CY2016Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
2708000
CY2016Q4 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
143000
CY2016Q4 us-gaap Liabilities Current
LiabilitiesCurrent
6918000
CY2016Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
493000
CY2016Q4 us-gaap Liabilities
Liabilities
7411000
CY2016Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2017Q4 spro Common Units Value
CommonUnitsValue
0
CY2016Q4 spro Common Units Value
CommonUnitsValue
0
CY2016Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2017Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-96840000
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
84602000
CY2016Q4 us-gaap Stockholders Equity
StockholdersEquity
-45440000
CY2017Q4 us-gaap Minority Interest
MinorityInterest
355000
CY2016Q4 us-gaap Minority Interest
MinorityInterest
-3808000
CY2017Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
84957000
CY2016Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-49248000
CY2017Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
93479000
CY2016Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
13772000
CY2016Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
0
CY2016Q4 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
206000
CY2017Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1164000
CY2017Q4 spro Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
4321000
CY2017Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
223000
CY2017Q4 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
143000
CY2017Q4 us-gaap Liabilities Current
LiabilitiesCurrent
8157000
CY2017Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
365000
CY2017Q4 us-gaap Assets
Assets
93479000
CY2017Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3470000
CY2017Q4 us-gaap Liabilities
Liabilities
8522000
CY2017Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2017Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2016Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2017Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
60000000
CY2017Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
14369182
CY2016Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
0
CY2017Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
14369182
CY2016Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
0
CY2017 us-gaap Operating Expenses
OperatingExpenses
43709000
CY2017 us-gaap Operating Income Loss
OperatingIncomeLoss
-41730000
CY2015 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-2999000
CY2017 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1844000
CY2015 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
174000
CY2016 us-gaap Profit Loss
ProfitLoss
-32641000
CY2015 us-gaap Profit Loss
ProfitLoss
-13153000
CY2015 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
252807
CY2016 us-gaap Net Income Loss
NetIncomeLoss
-25491000
CY2015 us-gaap Net Income Loss
NetIncomeLoss
-10154000
CY2015 us-gaap Redeemable Preferred Stock Dividends
RedeemablePreferredStockDividends
932000
CY2016 spro Accretion Of Redeemable Bridge Units And Redeemable Convertible Preferred Shares To Redemption Value
AccretionOfRedeemableBridgeUnitsAndRedeemableConvertiblePreferredSharesToRedemptionValue
996000
CY2015 spro Accretion Of Redeemable Bridge Units And Redeemable Convertible Preferred Shares To Redemption Value
AccretionOfRedeemableBridgeUnitsAndRedeemableConvertiblePreferredSharesToRedemptionValue
2341000
CY2016 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-29928000
CY2015 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-13427000
CY2016 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-95.87
CY2015 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-53.11
CY2015 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-12832000
CY2015 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-13153000
CY2016 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
312169
CY2014Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-6113000
CY2015 us-gaap Share Based Compensation
ShareBasedCompensation
21000
CY2017 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-83000
CY2017 us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
707000
CY2016 us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
294000
CY2015 us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
10000
CY2017 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
575000
CY2016 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
966000
CY2015 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
280000
CY2017 spro Increase Decrease In Tax Incentives Receivable
IncreaseDecreaseInTaxIncentivesReceivable
1811000
CY2016 spro Increase Decrease In Tax Incentives Receivable
IncreaseDecreaseInTaxIncentivesReceivable
144000
CY2017Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2017Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2017 us-gaap Revenue From Grants
RevenueFromGrants
1979000
CY2016 us-gaap Revenue From Grants
RevenueFromGrants
335000
CY2017 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
32869000
CY2017 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10840000
CY2017 spro Fair Value Adjustment Of Derivative Liability
FairValueAdjustmentOfDerivativeLiability
-1541000
CY2016 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
580000
CY2017 us-gaap Profit Loss
ProfitLoss
-39886000
CY2017 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-1143000
CY2015 spro Cumulative Dividends On Redeemable Convertible Preferred Units
CumulativeDividendsOnRedeemableConvertiblePreferredUnits
-932000
CY2015 spro Stockholders Equity Accretion Of Bridge Units To Redemption Value
StockholdersEquityAccretionOfBridgeUnitsToRedemptionValue
2307000
CY2015 spro Stockholders Equity Accretion Of Preferred Units To Redemption Value
StockholdersEquityAccretionOfPreferredUnitsToRedemptionValue
34000
CY2015 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
21000
CY2015Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-18553000
CY2016 spro Cumulative Dividends On Redeemable Convertible Preferred Units
CumulativeDividendsOnRedeemableConvertiblePreferredUnits
-3441000
CY2016 spro Stockholders Equity Accretion Of Redeemable Preferred Units To Redemption Value
StockholdersEquityAccretionOfRedeemablePreferredUnitsToRedemptionValue
969000
CY2016 spro Stockholders Equity Accretion Of Bridge Units To Redemption Value
StockholdersEquityAccretionOfBridgeUnitsToRedemptionValue
27000
CY2016 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
180000
CY2017 spro Stockholders Equity Accretion Of Bridge Units To Redemption Value
StockholdersEquityAccretionOfBridgeUnitsToRedemptionValue
576000
CY2017 spro Cumulative Dividends On Redeemable Convertible Preferred Units
CumulativeDividendsOnRedeemableConvertiblePreferredUnits
-3261000
CY2017 spro Stockholders Equity Accretion Of Redeemable Preferred Units To Redemption Value
StockholdersEquityAccretionOfRedeemablePreferredUnitsToRedemptionValue
369000
CY2017 spro Cumulative Dividends On Redeemable Convertible Preferred Shares
CumulativeDividendsOnRedeemableConvertiblePreferredShares
-2885000
CY2017 spro Stockholders Equity Accretion Of Preferred Stock To Redemption Value
StockholdersEquityAccretionOfPreferredStockToRedemptionValue
263000
CY2017 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
107018000
CY2017 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1427000
CY2016 spro Issuance Of Stock For License
IssuanceOfStockForLicense
4595000
CY2015 spro Issuance Of Stock For License
IssuanceOfStockForLicense
3517000
CY2017 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
363000
CY2016 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
279000
CY2015 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
11000
CY2017 us-gaap Share Based Compensation
ShareBasedCompensation
1427000
CY2016 us-gaap Share Based Compensation
ShareBasedCompensation
180000
CY2016 us-gaap Increase Decrease In Deposits
IncreaseDecreaseInDeposits
-53000
CY2015 us-gaap Increase Decrease In Deposits
IncreaseDecreaseInDeposits
-150000
CY2017 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
2349000
CY2016 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-644000
CY2015 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
671000
CY2017 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
1315000
CY2016 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
2322000
CY2015 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
409000
CY2017 us-gaap Increase Decrease In Other Deferred Liability
IncreaseDecreaseInOtherDeferredLiability
-128000
CY2016 us-gaap Increase Decrease In Other Deferred Liability
IncreaseDecreaseInOtherDeferredLiability
-84000
CY2016 us-gaap Increase Decrease In Customer Advances And Deposits
IncreaseDecreaseInCustomerAdvancesAndDeposits
-929000
CY2015 us-gaap Increase Decrease In Customer Advances And Deposits
IncreaseDecreaseInCustomerAdvancesAndDeposits
-470000
CY2015 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
-0.009
CY2015 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
-0.052
CY2015 us-gaap Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
0.003
CY2015 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
0.102
CY2015 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
0.296
CY2016 spro Issuance Of Additional Shares Of Common Stock To Minority Investors Under Antidilutive Rights
IssuanceOfAdditionalSharesOfCommonStockToMinorityInvestorsUnderAntidilutiveRights
980000
CY2015 spro Issuance Of Additional Shares Of Common Stock To Minority Investors Under Antidilutive Rights
IssuanceOfAdditionalSharesOfCommonStockToMinorityInvestorsUnderAntidilutiveRights
1459000
CY2015 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
728000
CY2015 spro Deferred Offering Costs Included In Accounts Payable And Accrued Expenses
DeferredOfferingCostsIncludedInAccountsPayableAndAccruedExpenses
11000
CY2017 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-39111000
CY2016 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-28959000
CY2015 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-9608000
CY2017 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
27000
CY2016 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
830000
CY2015 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
232000
CY2017 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-27000
CY2016 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-830000
CY2015 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-232000
CY2017 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
77749000
CY2017 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
3574000
CY2015 us-gaap Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
30000
CY2017 us-gaap Payments To Minority Shareholders
PaymentsToMinorityShareholders
1175000
CY2017 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
116111000
CY2016 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
34413000
CY2015 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
15275000
CY2017 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
76973000
CY2016 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
4624000
CY2015 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
5435000
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
5691000
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
256000
CY2017 spro Conversion Of Bridge Units Into Preferred Units
ConversionOfBridgeUnitsIntoPreferredUnits
8500000
CY2015 spro Conversion Of Bridge Units Into Preferred Units
ConversionOfBridgeUnitsIntoPreferredUnits
8000000
CY2017 spro Conversion Of Preferred Stock To Common Stock
ConversionOfPreferredStockToCommonStock
107018000
CY2017 spro Settlement Of Derivative Liability Upon Issuance Of Preferred Units
SettlementOfDerivativeLiabilityUponIssuanceOfPreferredUnits
944000
CY2015 spro Settlement Of Derivative Liability Upon Issuance Of Preferred Units
SettlementOfDerivativeLiabilityUponIssuanceOfPreferredUnits
888000
CY2016 spro Issuance Of Tranche Rights With Preferred Units
IssuanceOfTrancheRightsWithPreferredUnits
909000
CY2015 spro Issuance Of Tranche Rights With Preferred Units
IssuanceOfTrancheRightsWithPreferredUnits
2401000
CY2016 spro Deemed Contribution Of Capital
DeemedContributionOfCapital
2408000
CY2015 spro Deemed Contribution Of Capital
DeemedContributionOfCapital
1419000
CY2016 spro Settlement Of Derivative Liability Upon Issuance Of Bridge Units
SettlementOfDerivativeLiabilityUponIssuanceOfBridgeUnits
305000
CY2016 us-gaap Payments Of Derivative Issuance Costs
PaymentsOfDerivativeIssuanceCosts
908000
CY2017 spro Accretion Of Redeemable Convertible Preferred Units And Stock To Redemption Value
AccretionOfRedeemableConvertiblePreferredUnitsAndStockToRedemptionValue
632000
CY2016 spro Accretion Of Redeemable Convertible Preferred Units And Stock To Redemption Value
AccretionOfRedeemableConvertiblePreferredUnitsAndStockToRedemptionValue
969000
CY2015 spro Accretion Of Redeemable Convertible Preferred Units And Stock To Redemption Value
AccretionOfRedeemableConvertiblePreferredUnitsAndStockToRedemptionValue
34000
CY2017 spro Accretion Of Bridge Units To Redemption Value
AccretionOfBridgeUnitsToRedemptionValue
576000
CY2016 spro Accretion Of Bridge Units To Redemption Value
AccretionOfBridgeUnitsToRedemptionValue
27000
CY2015 spro Accretion Of Bridge Units To Redemption Value
AccretionOfBridgeUnitsToRedemptionValue
2307000
CY2017 us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Use of Estimates </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;">&nbsp;</p> <p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, the accrual for research and development expenses, the valuation of common shares prior to the Company&#8217;s IPO, the valuation of share-based awards and the valuation of derivative liabilities. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates, as there are changes in circumstances, facts and experience. Actual results may differ from those estimates or assumptions. </p></div>
CY2017 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Concentrations of Credit Risk and of Significant Suppliers </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;">&nbsp;</p> <p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains most of its cash and cash equivalents at one accredited financial institution. The Company does not believe that it is subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships. </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;">&nbsp;</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is dependent on third-party manufacturers to supply products for research and development activities in its programs. In particular, the Company relies and expects to continue to rely on a small number of manufacturers to supply it with its requirements for the active pharmaceutical ingredients and formulated drugs related to these programs. These programs could be adversely affected by a significant interruption in the supply of active pharmaceutical ingredients and formulated drugs. </p></div>
CY2017 spro Entity Incorporation Month And Year
EntityIncorporationMonthAndYear
2013-12
CY2017 dei Entity Incorporation State Country Name
EntityIncorporationStateCountryName
Delaware
CY2017 us-gaap Business Acquisition Date Of Acquisition Agreement1
BusinessAcquisitionDateOfAcquisitionAgreement1
2017-06-30
CY2017 spro Business Combination Exchange Ratio
BusinessCombinationExchangeRatio
1
CY2016Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
0
CY2017Q4 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0
CY2016Q4 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0
CY2017Q4 us-gaap Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
0
CY2016Q4 us-gaap Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
0
CY2017Q4 us-gaap Fair Value Liabilities Level1 To Level2 Transfers Amount
FairValueLiabilitiesLevel1ToLevel2TransfersAmount
0
CY2016Q4 us-gaap Fair Value Liabilities Level1 To Level2 Transfers Amount
FairValueLiabilitiesLevel1ToLevel2TransfersAmount
0
CY2017Q4 us-gaap Fair Value Liabilities Level2 To Level1 Transfers Amount
FairValueLiabilitiesLevel2ToLevel1TransfersAmount
0
CY2016Q4 us-gaap Fair Value Liabilities Level2 To Level1 Transfers Amount
FairValueLiabilitiesLevel2ToLevel1TransfersAmount
0
CY2017 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Net
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet
0
CY2016 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Net
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet
0
CY2017 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Transfers Net
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet
0
CY2016 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Transfers Net
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet
0
CY2017Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1807000
CY2016Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1790000
CY2017Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
643000
CY2016Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
290000
CY2017Q4 spro Accrued External Research And Development Expenses Current
AccruedExternalResearchAndDevelopmentExpensesCurrent
1770000
CY2016Q4 spro Accrued External Research And Development Expenses Current
AccruedExternalResearchAndDevelopmentExpensesCurrent
627000
CY2017Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1369000
CY2016Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1018000
CY2017Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
878000
CY2016Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1062000
CY2017Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
304000
CY2016Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
221000
CY2017Q2 spro Convertible Preferred Shares To Common Shares Conversion Ratio
ConvertiblePreferredSharesToCommonSharesConversionRatio
1
CY2017 spro Minimum Value Of Proceeds From Initial Public Offering For Conversion Of Preferred Units
MinimumValueOfProceedsFromInitialPublicOfferingForConversionOfPreferredUnits
50000000
CY2017 spro Temporary Equity Percentage Of Voting To Be Held By Holders Of Senior Preferred Stock For Deemed Liquidation Preference
TemporaryEquityPercentageOfVotingToBeHeldByHoldersOfSeniorPreferredStockForDeemedLiquidationPreference
0.60
CY2017 us-gaap Preferred Stock Dividend Rate Percentage
PreferredStockDividendRatePercentage
0.08
CY2017 us-gaap Preferred Stock Dividends Per Share Cash Paid
PreferredStockDividendsPerShareCashPaid
0
CY2016 us-gaap Preferred Stock Dividends Per Share Cash Paid
PreferredStockDividendsPerShareCashPaid
0
CY2017 us-gaap Preferred Stock Dividends Per Share Declared
PreferredStockDividendsPerShareDeclared
0
CY2016 us-gaap Preferred Stock Dividends Per Share Declared
PreferredStockDividendsPerShareDeclared
0
CY2017 spro Temporary Equity Redemption Date
TemporaryEquityRedemptionDate
2021-02-01
CY2017Q4 spro Temporary Equity Redemption Number Of Annual Installments
TemporaryEquityRedemptionNumberOfAnnualInstallments
3
CY2017 spro Preferred Stock Notice Period For Redemption
PreferredStockNoticePeriodForRedemption
P60D
CY2017Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
61917986
CY2017Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2017 us-gaap Common Stock Voting Rights
CommonStockVotingRights
Each share of common stock entitles the holder to one vote on all matters submitted to a vote of the Company’s stockholders.
CY2016 us-gaap Stock Repurchased And Retired During Period Shares
StockRepurchasedAndRetiredDuringPeriodShares
21116
CY2016Q4 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
0.001
CY2017Q4 spro Unvested Restricted Common Units Outstanding
UnvestedRestrictedCommonUnitsOutstanding
0
CY2016Q4 spro Unvested Restricted Common Units Outstanding
UnvestedRestrictedCommonUnitsOutstanding
7062
CY2015Q4 spro Unvested Restricted Common Units Outstanding
UnvestedRestrictedCommonUnitsOutstanding
75210
CY2016Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
800000
CY2016 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P3Y1M6D
CY2017Q3 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Lower Range Limit
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
5.90
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.020
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.013
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.015
CY2017 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y1M6D
CY2016 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y3M18D
CY2015 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y3M18D
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.771
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.765
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.626
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.000
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.000
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.000
CY2017 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2016 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2015 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2017 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-38706000
CY2016 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-27148000
CY2017 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-1180000
CY2016 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-5493000
CY2015 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-321000
CY2017 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-39886000
CY2016 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-32641000
CY2017 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.340
CY2016 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.340
CY2015 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.340
CY2017 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
-0.033
CY2016 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
-0.017
CY2017 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
-0.053
CY2016 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
-0.044
CY2017 us-gaap Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
0.001
CY2016 us-gaap Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
0.023
CY2017 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
-0.001
CY2016 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
0.048
CY2017 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
0.238
CY2017 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
0.188
CY2016 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
0.330
CY2017Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
21754000
CY2016Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
16406000
CY2017Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-12076000
CY2017Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards State And Local
DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
76000000
CY2017Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
2022000
CY2016Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
697000
CY2017Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
743000
CY2016Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
49000
CY2017Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
24519000
CY2016Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
17152000
CY2017Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
24519000
CY2016Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
17152000
CY2017Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Domestic
DeferredTaxAssetsOperatingLossCarryforwardsDomestic
76400000
CY2017 spro Operating Loss Carryforward Federal And State Expiration Year Start
OperatingLossCarryforwardFederalAndStateExpirationYearStart
2033
CY2017Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Foreign
DeferredTaxAssetsOperatingLossCarryforwardsForeign
4300000
CY2017 spro Ownership Change Increase In Ownership By Maximum Percentage
OwnershipChangeIncreaseInOwnershipByMaximumPercentage
0.50
CY2017 spro Ownership Change Increase In Ownership Percentage Term
OwnershipChangeIncreaseInOwnershipPercentageTerm
P3Y
CY2015Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
6157000
CY2017 spro Valuation Allowance Deferred Tax Asset Increase In Amount
ValuationAllowanceDeferredTaxAssetIncreaseInAmount
7367000
CY2016 spro Valuation Allowance Deferred Tax Asset Increase In Amount
ValuationAllowanceDeferredTaxAssetIncreaseInAmount
10995000
CY2017Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2016Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2017Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2016Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2017 spro Tax Cuts And Jobs Act Of2017 Net Operating Losses Limitation Percentage
TaxCutsAndJobsActOf2017NetOperatingLossesLimitationPercentage
0.80
CY2017 spro Tax Cuts And Jobs Act Of2017 Incomplete Accounting Change In Tax Rate Decrease In Deferred Tax Asset
TaxCutsAndJobsActOf2017IncompleteAccountingChangeInTaxRateDecreaseInDeferredTaxAsset
9400000
CY2017Q4 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
820000
CY2017Q4 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
808000
CY2017Q4 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
499000
CY2017Q4 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
2127000
CY2017 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
800000
CY2016 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
400000
CY2015 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
100000
CY2017 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2011296
CY2016 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2642784
CY2015 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1428971
CY2017 us-gaap Defined Contribution Plan Employer Matching Contribution Percent
DefinedContributionPlanEmployerMatchingContributionPercent
0
CY2016 us-gaap Defined Contribution Plan Employer Matching Contribution Percent
DefinedContributionPlanEmployerMatchingContributionPercent
0
CY2015 us-gaap Defined Contribution Plan Employer Matching Contribution Percent
DefinedContributionPlanEmployerMatchingContributionPercent
0
CY2017Q1 us-gaap Revenue From Grants
RevenueFromGrants
140000
CY2017Q2 us-gaap Revenue From Grants
RevenueFromGrants
249000
CY2017Q3 us-gaap Revenue From Grants
RevenueFromGrants
597000
CY2017Q4 us-gaap Revenue From Grants
RevenueFromGrants
993000
CY2017Q1 us-gaap Operating Expenses
OperatingExpenses
7739000
CY2017Q2 us-gaap Operating Expenses
OperatingExpenses
10414000
CY2017Q3 us-gaap Operating Expenses
OperatingExpenses
10563000
CY2017Q4 us-gaap Operating Expenses
OperatingExpenses
14993000
CY2017Q1 us-gaap Profit Loss
ProfitLoss
-6411000
CY2017Q2 us-gaap Profit Loss
ProfitLoss
-9763000
CY2017Q3 us-gaap Profit Loss
ProfitLoss
-9844000
CY2017Q4 us-gaap Profit Loss
ProfitLoss
-13868000
CY2017Q1 us-gaap Net Income Loss
NetIncomeLoss
-5876000
CY2017Q2 us-gaap Net Income Loss
NetIncomeLoss
-9169000
CY2017Q3 us-gaap Net Income Loss
NetIncomeLoss
-9836000
CY2017Q4 us-gaap Net Income Loss
NetIncomeLoss
-13862000
CY2017Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-7130000
CY2017Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-12121000
CY2016Q3 us-gaap Operating Expenses
OperatingExpenses
7914000
CY2017Q4 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-14770000
CY2017Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-21.60
CY2017Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-36.21
CY2017Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-36.02
CY2017Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.59
CY2017Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
330075
CY2017Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
334788
CY2017Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
335285
CY2017Q4 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
9273783
CY2016Q4 us-gaap Revenue From Grants
RevenueFromGrants
335000
CY2016Q1 us-gaap Operating Expenses
OperatingExpenses
8417000
CY2016Q2 us-gaap Operating Expenses
OperatingExpenses
8080000
CY2016Q4 us-gaap Operating Expenses
OperatingExpenses
9145000
CY2016Q1 us-gaap Profit Loss
ProfitLoss
-8430000
CY2016Q2 us-gaap Profit Loss
ProfitLoss
-8096000
CY2016Q3 us-gaap Profit Loss
ProfitLoss
-7918000
CY2016Q4 us-gaap Profit Loss
ProfitLoss
-8197000
CY2016Q1 us-gaap Net Income Loss
NetIncomeLoss
-5905000
CY2016Q2 us-gaap Net Income Loss
NetIncomeLoss
-6059000
CY2016Q3 us-gaap Net Income Loss
NetIncomeLoss
-6316000
CY2016Q4 us-gaap Net Income Loss
NetIncomeLoss
-7211000
CY2016Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-6257000
CY2016Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-7928000
CY2016Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-7410000
CY2016Q4 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-8333000
CY2016Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-21.51
CY2016Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-25.30
CY2016Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-23.23
CY2016Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-25.68
CY2016Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
290884
CY2016Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
313414
CY2016Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
318948
CY2016Q4 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
324521

Files In Submission

Name View Source Status
0001564590-18-007402-index-headers.html Edgar Link pending
0001564590-18-007402-index.html Edgar Link pending
0001564590-18-007402.txt Edgar Link pending
0001564590-18-007402-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
g20180402163246826462.jpg Edgar Link pending
g20180402163247326463.jpg Edgar Link pending
g20180402163248096464.jpg Edgar Link pending
g20180402163248103465.jpg Edgar Link pending
g20180402163248111466.jpg Edgar Link pending
g20180402163248121467.jpg Edgar Link pending
g20180402163248587468.jpg Edgar Link pending
g20180402163248597469.jpg Edgar Link pending
g20180402163248641470.jpg Edgar Link pending
g20180402163248651471.jpg Edgar Link pending
g20180402163248660472.jpg Edgar Link pending
g20180402163303867473.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
spro-10k_20171231.htm Edgar Link pending
spro-20171231.xml Edgar Link completed
spro-20171231.xsd Edgar Link pending
spro-20171231_cal.xml Edgar Link unprocessable
spro-20171231_def.xml Edgar Link unprocessable
spro-20171231_lab.xml Edgar Link unprocessable
spro-20171231_pre.xml Edgar Link unprocessable
spro-ex109_1873.htm Edgar Link pending
spro-ex211_429.htm Edgar Link pending
spro-ex231_1098.htm Edgar Link pending
spro-ex311_6.htm Edgar Link pending
spro-ex312_7.htm Edgar Link pending
spro-ex321_8.htm Edgar Link pending
spro-ex322_9.htm Edgar Link pending